MT. KISCO, N.Y., Dec. 07, 2016 -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today announced that a Definitive Agreement has been reached with Dr. Lilliana Ramirez to endorse and assist with the development of a new line of skincare products based on Immudyne’s proprietary Yeast Beta Glucan ingredient. The brand, Inate MD, will be launched nationally January 1, 2017.
Dr. Lilliana Ramirez is a practicing, board certified dermatologist with a distinguished track record in medicine and academics. She graduated Magna Cum Laude from the University of Puerto Rico and has received many awards for both her research and the practice of medicine.
“Immudyne is partnering with and associating our brand with yet another highly accomplished dermatologist,” stated Mark McLaughlin, President and CEO of Immudyne.
“I’m very pleased to be working with Immudyne,” said Dr. Ramirez. "The Inate MD skincare line is backed by excellent science and a great management team. I think my patients and consumers across the county will enjoy and benefit from use of the Inate MD product line.”
The Inate MD line will initially be available exclusively online and will consist of a Serum, Moisturizer, Instant Wrinkle Eraser and an optional nutritional supplement to support healthier skin and the human Immune System.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which are, in some cases, beyond the control of Immudyne. Actual events, performance or results could differ materially from the anticipated events, performance or results expressed or implied by such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
About ImmuDyne, Inc.
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. ImmuDyne also has a majority owned direct marketing division that markets immune support, skincare and hair loss products directly to consumers around the world. All of the Company’s intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Contact: lmmuDyne, Inc. Mark McLaughlin: +1-914-714-8901


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Anta Sports Expands Global Footprint With Strategic Puma Stake
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



